PharmacyCodes



Quinoscan en es it fr

Categorie

Quinoscan Les marques, Quinoscan Analogs

Quinoscan Les marques melange

  • No information avaliable

    • Quinoscan Formule chimique

    C18H26ClN3

    Quinoscan RX lien

    http://www.rxlist.com/cgi/generic2/hquine2.htm

    Quinoscan FDA fiche

    Quinoscan FDA

    Quinoscan msds (fiche de securite des materiaux)

    Quinoscan MSDS

    Quinoscan Synthese de reference

    Aucune information disponible

    Quinoscan Poids moleculaire

    319.872 g/mol

    Quinoscan Point de fusion

    289 oC

    Quinoscan H2O Solubilite

    10,6 mg / L

    Quinoscan Etat

    Solid

    Quinoscan LogP

    4.474

    Quinoscan Formes pharmaceutiques

    Tablet

    Quinoscan Indication

    Pour le traitement suppressif et de crises aiguës de paludisme à P. vivax, P. malariae, P. ovale et des souches sensibles de P. falciparum, l'agent de deuxième ligne dans le traitement de la polyarthrite rhumatoïde

    Quinoscan Pharmacologie

    La chloroquine est le prototype de médicament anti paludisme, la plus largement utilisée pour traiter tous les types de paludisme, sauf pour les maladies causées par la chloroquine de Plasmodium falciparum résistant. Il est très efficace contre les formes érythrocytaires de Plasmodium vivax, Plasmodium ovale et Plasmodium malariae, les souches sensibles de Plasmodium falciparum et des gamétocytes de Plasmodium vivax. Etre alcalin, le médicament atteint forte concentration dans les vacuoles alimentaires du parasite et soulève son pH. Il se trouve à induire l'agglutination rapide du pigment. La chloroquine inhibe l'enzyme polymérase parasitaires hème qui convertit l'hème toxiques dans non toxique hemazoin, ce qui entraîne l'accumulation de toxiques dans l'hème du parasite. Il peut également interférer avec la biosynthèse des acides nucléiques.

    Quinoscan Absorption

    Complètement absorbé par les voies gastro-intestinales

    Quinoscan Toxicite

    Aucune information disponible

    Quinoscan Information pour les patients

    PATIENT INFORMATION

    Complete blood cell counts should be made periodically if patients are given prolonged therapy. If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuance of the drug should be considered. The drug should be administered with caution to patients having G-6-PD (glucose-6 phosphate dehydrogenase) deficiency.

    In patients with preexisting auditory damage, chloroquine should be administered with caution. In case of any defects in hearing, chloroquine should be immediately discontinued, and the patient closely observed.

    Since this drug is known to concentrate in the liver, it should be used with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs.

    Patients with history of epilepsy should be advised about the risk of chloroquine provoking seizures.

    Because of the potential for serious adverse reactions in nursing infants from chloroquine, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the potential clinical benefit of the drug to the mother.

    Irreversible retinal damage has been observed in some patients who had received long-term or high-dosage 4-aminoquinoline therapy. Retinopathy has been reported to be dose related.

    Follow Rxlist link and drugs.com link for detailed patient information.

    Quinoscan Organismes affectes

    Plasmodium